Bayer (BAYRY) announced that its wholly owned and independently operating subsidiary, Asklepios BioPharmaceutical, Inc. (AskBio), initiated recruitment in the mid-stage study REGENERATE-PD. REGENERATE-PD is a phase II study evaluating the efficacy and safety of AB-1005, an investigational adeno- associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. Subjects will receive either bilateral image-guided infusion of AAV2 ...